BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Myers RP, Ramji A, Bilodeau M, Wong S, Feld JJ. An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol 2012;26:359-75. [PMID: 22720279 DOI: 10.1155/2012/947676] [Cited by in Crossref: 40] [Cited by in F6Publishing: 54] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Turner SJ, Brown J, Paladino JA. Protease Inhibitors for Hepatitis C: Economic Implications. PharmacoEconomics 2013;31:739-51. [DOI: 10.1007/s40273-013-0073-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
2 Shah HA, Heathcote J, Feld JJ. A Canadian screening program for hepatitis C: is now the time? CMAJ 2013;185:1325-8. [PMID: 24082023 DOI: 10.1503/cmaj.121872] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
3 O'Keefe-Markman C, Lea KD, McCabe C, Hyshka E, Bubela T. Social values for health technology assessment in Canada: a scoping review of hepatitis C screening, diagnosis and treatment. BMC Public Health 2020;20:89. [PMID: 31959155 DOI: 10.1186/s12889-020-8190-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Al-Judaibi B. The new era of hepatitis C virus therapy. Saudi J Gastroenterol 2015;21:345-54. [PMID: 26655128 DOI: 10.4103/1319-3767.170947] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
5 Song PP, Xia JF, Inagaki Y, Hasegawa K, Sakamoto Y, Kokudo N, Tang W. Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma. World J Gastroenterol 2016; 22(1): 262-274 [PMID: 26755875 DOI: 10.3748/wjg.v22.i1.262] [Cited by in CrossRef: 69] [Cited by in F6Publishing: 61] [Article Influence: 11.5] [Reference Citation Analysis]
6 Fischer B, Murphy Y, Rudzinski K, MacPherson D. Illicit drug use and harms, and related interventions and policy in Canada: A narrative review of select key indicators and developments since 2000. Int J Drug Policy 2016;27:23-35. [PMID: 26359046 DOI: 10.1016/j.drugpo.2015.08.007] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
7 Wong WWL, Tu HA, Feld JJ, Wong T, Krahn M. Cost-effectiveness of screening for hepatitis C in Canada. CMAJ 2015;187:E110-21. [PMID: 25583667 DOI: 10.1503/cmaj.140711] [Cited by in Crossref: 41] [Cited by in F6Publishing: 45] [Article Influence: 5.9] [Reference Citation Analysis]
8 Pai R, Ramji A, Lee SS, Wong WW, Yoshida EM. Chronic hepatitis C in Western Canada: a survey of practice patterns among gastroenterologists in Alberta and British Columbia. Can J Gastroenterol Hepatol 2014;28:e1-4. [PMID: 24212914 DOI: 10.1155/2014/651717] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
9 Cooper CL, Klein MB. HIV/hepatitis C virus coinfection management: changing guidelines and changing paradigms. HIV Med 2014;15:621-4. [PMID: 24802099 DOI: 10.1111/hiv.12161] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
10 Hull M, Shafran S, Wong A, Tseng A, Giguère P, Barrett L, Haider S, Conway B, Klein M, Cooper C. CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and Treatment. Can J Infect Dis Med Microbiol 2016;2016:4385643. [PMID: 27471521 DOI: 10.1155/2016/4385643] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
11 Woolhouse S, Cooper E, Pickard A. "It gives me a sense of belonging": providing integrated health care and treatment to people with HCV engaged in a psycho-educational support group. Int J Drug Policy 2013;24:550-7. [PMID: 23860471 DOI: 10.1016/j.drugpo.2013.05.018] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
12 Minuk GY, O'Brien M, Hawkins K, Emokpare D, McHattie J, Harris P, Worobetz L, Doucette K, Kaita K, Wong S, Pinette G, Uhanova J. Treatment of chronic hepatitis C in a Canadian Aboriginal population: results from the PRAIRIE study. Can J Gastroenterol 2013;27:707-10. [PMID: 24340315 DOI: 10.1155/2013/963694] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
13 Barr RG, Ferraioli G, Palmeri ML, Goodman ZD, Garcia-Tsao G, Rubin J, Garra B, Myers RP, Wilson SR, Rubens D, Levine D. Elastography Assessment of Liver Fibrosis: Society of Radiologists in Ultrasound Consensus Conference Statement. Radiology 2015;276:845-61. [PMID: 26079489 DOI: 10.1148/radiol.2015150619] [Cited by in Crossref: 276] [Cited by in F6Publishing: 238] [Article Influence: 39.4] [Reference Citation Analysis]
14 Myers RP, Krajden M, Bilodeau M, Kaita K, Marotta P, Peltekian K, Ramji A, Estes C, Razavi H, Sherman M. Burden of disease and cost of chronic hepatitis C infection in Canada. Can J Gastroenterol Hepatol. 2014;28:243-250. [PMID: 24839620 DOI: 10.1155/2014/317623] [Cited by in Crossref: 91] [Cited by in F6Publishing: 88] [Article Influence: 13.0] [Reference Citation Analysis]
15 Fralick M, Feld JJ. Hepatitis C virus infection. CMAJ 2015;187:1159. [PMID: 26303246 DOI: 10.1503/cmaj.140290] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
16 Cox J, Maurais E, Hu L, Moodie EE, Law S, Bozinoff N, Potter M, Rollet K, Hull M, Tyndall M, Cooper C, Gill J, Saeed S, Klein MB; Canadian Co-infection Cohort (CTN 222). Correlates of drug use cessation among participants in the Canadian HIV-HCV Co-infection Cohort. Drug Alcohol Depend 2014;137:121-8. [PMID: 24559606 DOI: 10.1016/j.drugalcdep.2014.01.014] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
17 Wong WW, Wong J, Bremner KE, Saeed Y, Mason K, Phoon A, Feng Z, Feld JJ, Mitsakakis N, Powis J, Krahn M. Time Costs and Out-of-Pocket Costs in Patients With Chronic Hepatitis C in a Publicly Funded Health System. Value in Health 2022;25:247-56. [DOI: 10.1016/j.jval.2021.08.006] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Iversen J, Grebely J, Topp L, Wand H, Dore G, Maher L. Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999-2011. J Viral Hepat 2014;21:198-207. [PMID: 24438681 DOI: 10.1111/jvh.12129] [Cited by in Crossref: 97] [Cited by in F6Publishing: 93] [Article Influence: 10.8] [Reference Citation Analysis]
19 Dowsett LE, Coward S, Lorenzetti DL, MacKean G, Clement F. Living with Hepatitis C Virus: A Systematic Review and Narrative Synthesis of Qualitative Literature. Can J Gastroenterol Hepatol 2017;2017:3268650. [PMID: 28529936 DOI: 10.1155/2017/3268650] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
20 Janjua NZ, Wong S, Abdia Y, Jeong D, Buller-Taylor T, Adu PA, Samji H, Wilton J, Pearce M, Butt ZA, Yu A, Binka M, Bartlett S, Alvarez M, Krajden M. Impact of direct-acting antivirals for HCV on mortality in a large population-based cohort study. J Hepatol 2021:S0168-8278(21)00401-3. [PMID: 34097994 DOI: 10.1016/j.jhep.2021.05.028] [Reference Citation Analysis]
21 Myers RP, Shah H, Burak KW, Cooper C, Feld JJ. An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol Hepatol 2015;29:19-34. [PMID: 25585348 DOI: 10.1155/2015/692408] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 6.7] [Reference Citation Analysis]
22 Rosina F, Tosti ME, Borghesio E, Masocco M, Mele A, Coppola C, Milella M, Borgia G, Andreone P, Koch M. Pegylated interferon α plus ribavirin for the treatment of chronic hepatitis C: a multicentre independent study supported by the Italian Drug Agency. Dig Liver Dis. 2014;46:826-832. [PMID: 24986781 DOI: 10.1016/j.dld.2014.05.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
23 Montero N, Favà A, Rodriguez E, Barrios C, Cruzado JM, Pascual J, Soler MJ. Treatment for hepatitis C virus-associated mixed cryoglobulinaemia. Cochrane Database Syst Rev 2018;5:CD011403. [PMID: 29734473 DOI: 10.1002/14651858.CD011403.pub2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
24 Stokes W, Fenton C, Clement F, James M, Ronksley P, Tang KL. The Efficacy and Safety of 12 Weeks of Sofosbuvir and Ledipasvir versus Sofosbuvir, Ledipasvir, and Ribavirin in Patients with Chronic Hepatitis C, Genotype 1, Who Have Cirrhosis and Have Failed Prior Therapy: A Systematic Review and Meta-Analysis. Can J Gastroenterol Hepatol 2017;2017:6468309. [PMID: 28367429 DOI: 10.1155/2017/6468309] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
25 Janjua NZ, Wong S, Darvishian M, Butt ZA, Yu A, Binka M, Alvarez M, Woods R, Yoshida EM, Ramji A, Feld J, Krajden M. The impact of SVR from direct-acting antiviral- and interferon-based treatments for HCV on hepatocellular carcinoma risk. J Viral Hepat. 2020;27:781-793. [PMID: 32187430 DOI: 10.1111/jvh.13295] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
26 Myers RP, Crotty P, Town S, English J, Fonseca K, Tellier R, Swain MG, McGregor SE, Heitman SJ, Hilsden RJ. Acceptability and yield of birth-cohort screening for hepatitis C virus in a Canadian population being screened for colorectal cancer: a cross-sectional study. CMAJ Open 2015;3:E62-7. [PMID: 25844371 DOI: 10.9778/cmajo.20140024] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
27 Sockalingam S, Blank D, Banga CA, Mason K, Dodd Z, Powis J. A novel program for treating patients with trimorbidity: hepatitis C, serious mental illness, and active substance use. Eur J Gastroenterol Hepatol. 2013;25:1377-1384. [PMID: 23680911 DOI: 10.1097/meg.0b013e3283624a28] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
28 Janjua NZ, Chong M, Kuo M, Woods R, Wong J, Yoshida EM, Sherman M, Butt ZA, Samji H, Cook D, Yu A, Alvarez M, Tyndall M, Krajden M. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada. J Hepatol. 2017;66:504-513. [PMID: 27818234 DOI: 10.1016/j.jhep.2016.10.028] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 8.8] [Reference Citation Analysis]
29 Naghdi R, Seto K, Klassen C, Emokpare D, Conway B, Kelley M, Yoshida E, Shah HA. A Hepatitis C Educational Needs Assessment of Canadian Healthcare Providers. Can J Gastroenterol Hepatol 2017;2017:5324290. [PMID: 28396854 DOI: 10.1155/2017/5324290] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
30 Li C, Li R, Zhang W. Progress in non-invasive detection of liver fibrosis. Cancer Biol Med 2018;15:124-36. [PMID: 29951337 DOI: 10.20892/j.issn.2095-3941.2018.0018] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 7.8] [Reference Citation Analysis]
31 Brown K, Labrie M, Coffin CS. Treatment of Genotype 2 and Genotype 3 Hepatitis C Virus (HCV) Infection in Human Immunodeficiency Virus Positive Patients. Curr HIV/AIDS Rep 2013;10:420-7. [DOI: 10.1007/s11904-013-0186-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
32 Barr RG, Ferraioli G, Palmeri ML, Goodman ZD, Garcia-tsao G, Rubin J, Garra B, Myers RP, Wilson SR, Rubens D, Levine D. Elastography Assessment of Liver Fibrosis: Society of Radiologists in Ultrasound Consensus Conference Statement. Ultrasound Quarterly 2016;32:94-107. [DOI: 10.1097/ruq.0000000000000209] [Cited by in Crossref: 64] [Cited by in F6Publishing: 17] [Article Influence: 10.7] [Reference Citation Analysis]
33 Ji H, Kozak RA, Biondi MJ, Pilon R, Vallee D, Liang BB, La D, Kim J, Van Domselaar G, Leonard L, Sandstrom P, Brooks J. Next generation sequencing of the hepatitis C virus NS5B gene reveals potential novel S282 drug resistance mutations. Virology 2015;477:1-9. [PMID: 25600207 DOI: 10.1016/j.virol.2014.12.037] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 4.0] [Reference Citation Analysis]
34 Smyth DJ, Webster D, Barrett L, MacMillan M, McKnight L, Schweiger F. Transitioning to highly effective therapies for the treatment of chronic hepatitis C virus infection: a policy statement and implementation guideline. Can J Gastroenterol Hepatol 2014;28:529-34. [PMID: 25390613 DOI: 10.1155/2014/109046] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
35 Smyth D, Webster D. Hepatitis C: pay now or pay later? Future Virology 2015;10:1285-90. [DOI: 10.2217/fvl.15.104] [Reference Citation Analysis]
36 Durand M, Wang Y, Venne F, Lelorier J, Tremblay CL, Abrahamowicz M. Diagnostic accuracy of algorithms to identify hepatitis C status, AIDS status, alcohol consumption and illicit drug use among patients living with HIV in an administrative healthcare database. Pharmacoepidemiol Drug Saf 2015;24:943-50. [PMID: 26114918 DOI: 10.1002/pds.3808] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
37 Tam E, Borgia S, Yoshida EM, Cooper C, Ford J, Vachon M, Sherman M, Halsey-brandt J. Real-world health care utilization in treatment of HCV: Results from the Canadian SIMPLE observational trial. CanLivJ 2019;2:91-107. [DOI: 10.3138/canlivj.2018-0024] [Reference Citation Analysis]
38 Thibault PA, Huys A, Dhillon P, Wilson JA. MicroRNA-122-dependent and -independent replication of Hepatitis C Virus in Hep3B human hepatoma cells. Virology 2013;436:179-90. [PMID: 23245472 DOI: 10.1016/j.virol.2012.11.007] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
39 Grebely J, Bilodeau M, Feld JJ, Bruneau J, Fischer B, Raven JF, Roberts E, Choucha N, Myers RP, Sagan SM, Wilson JA, Bialystok F, Tyrrell DL, Houghton M, Krajden M; National CIHR Research Training Program in Hepatitis C. The Second Canadian Symposium on hepatitis C virus: a call to action. Can J Gastroenterol 2013;27:627-32. [PMID: 24199209 DOI: 10.1155/2013/242405] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
40 Coppola N, Pisaturo M, Sagnelli C, Sagnelli E, Angelillo IF. Peg-interferon plus ribavirin with or without boceprevir or telaprevir for HCV genotype 1: a meta-analysis on the role of response predictors. PLoS One. 2014;9:e94542. [PMID: 24728219 DOI: 10.1371/journal.pone.0094542] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
41 Wu S, Kanda T, Nakamoto S, Imazeki F, Yokosuka O. Hepatitis C virus protease inhibitor-resistance mutations: Our experience and review. World J Gastroenterol 2013; 19(47): 8940-8948 [PMID: 24379619 DOI: 10.3748/wjg.v19.i47.8940] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
42 Tovo CV, Mattos AA, Almeida PRL. Chronic hepatitis C genotype 1 virus: Who should wait for treatment? World J Gastroenterol 2014; 20(11): 2867-2875 [PMID: 24659878 DOI: 10.3748/wjg.v20.i11.2867] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
43 Feld JJ. Treatment indication and response to standard of care with peginterferon and ribavirin in acute and chronic HCV infection. Best Practice & Research Clinical Gastroenterology 2012;26:429-44. [DOI: 10.1016/j.bpg.2012.09.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
44 Sebastiani G, Ghali P, Wong P, Klein MB, Deschenes M, Myers RP. Physicians' practices for diagnosing liver fibrosis in chronic liver diseases: a nationwide, Canadian survey. Can J Gastroenterol Hepatol 2014;28:23-30. [PMID: 24416739 DOI: 10.1155/2014/675409] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
45 Shah H, Bilodeau M, Burak KW, Cooper C, Klein M, Ramji A, Smyth D, Feld JJ; Canadian Association for the Study of the Liver. The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver. CMAJ 2018;190:E677-87. [PMID: 29866893 DOI: 10.1503/cmaj.170453] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 16.7] [Reference Citation Analysis]
46 Sebastiani G, Gkouvatsos K, Pantopoulos K. Chronic hepatitis C and liver fibrosis. World J Gastroenterol 2014; 20(32): 11033-11053 [PMID: 25170193 DOI: 10.3748/wjg.v20.i32.11033] [Cited by in CrossRef: 117] [Cited by in F6Publishing: 97] [Article Influence: 14.6] [Reference Citation Analysis]
47 Kapeluto J, Kadatz M, Wormsbecker A, Sidhu K, Yoshida EM. Screening, detecting and enhancing the yield of previously undiagnosed hepatitis B and C in patients with acute medical admissions to hospital: a pilot project undertaken at the Vancouver General Hospital. Can J Gastroenterol Hepatol 2014;28:315-8. [PMID: 24945186 DOI: 10.1155/2014/190210] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
48 O'Neil CR, Pang JX, Lee SS, Swain MG, Burak KW, Klein P, Myers RP, Kapler J, Gill MJ, Labrie M, Coffin CS. Treatment outcomes with telaprevir-based therapy for HIV/hepatitis C coinfected patients are comparable with hepatitis C monoinfected patients. Can J Infect Dis Med Microbiol 2015;26:293-6. [PMID: 26744584 DOI: 10.1155/2015/974871] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
49 Cooper CL, Galanakis C, Donelle J, Kwong J, Boyd R, Boucher L, Kendall CE. HCV-infected individuals have higher prevalence of comorbidity and multimorbidity: a retrospective cohort study. BMC Infect Dis 2019;19:712. [PMID: 31438873 DOI: 10.1186/s12879-019-4315-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
50 Ilyas F, Singh H, Anand N, Ahmed II. Intraocular pressure rise in the course of peginterferon alpha-2a, ribavirin, and boceprevir therapy for hepatitis C. Can J Ophthalmol. 2015;50:e112-e114. [PMID: 26651317 DOI: 10.1016/j.jcjo.2015.08.013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
51 Hilsden RJ, Macphail G, Grebely J, Conway B, Lee SS. Directly observed pegylated interferon plus self-administered ribavirin for the treatment of hepatitis C virus infection in people actively using drugs: a randomized controlled trial. Clin Infect Dis. 2013;57 Suppl 2:S90-S96. [PMID: 23884072 DOI: 10.1093/cid/cit327] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
52 Hull M, Shafran S, Tseng A, Giguère P, Klein MB, Cooper C. CIHR Canadian HIV Trials Network Co-Infection and Concurrent Diseases Core: Updated Canadian guidelines for the treatment of hepatitis C infection in HIV-hepatitis C coinfected adults. Can J Infect Dis Med Microbiol 2014;25:311-20. [PMID: 25587293 DOI: 10.1155/2014/251989] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
53 Jhaveri KS, Hosseini-Nik H, Sadoughi N, Janssen H, Feld JJ, Fischer S, Menezes R, Cheung AC. The development and validation of magnetic resonance elastography for fibrosis staging in primary sclerosing cholangitis. Eur Radiol. 2019;29:1039-1047. [PMID: 30051141 DOI: 10.1007/s00330-018-5619-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
54 Socías ME, Ti L, Wood E, Nosova E, Hull M, Hayashi K, Debeck K, Milloy MJ. Disparities in uptake of direct-acting antiviral therapy for hepatitis C among people who inject drugs in a Canadian setting. Liver Int 2019;39:1400-7. [PMID: 30653809 DOI: 10.1111/liv.14043] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 9.3] [Reference Citation Analysis]
55 Marotta P, Bailey R, Elkashab M, Farley J, Feinman SV, Peltekian K, Poliquin M, Witt-Sullivan H, Rampakakis E, Drolet M, Cooper C. Real-world effectiveness of peginterferon α-2b plus ribavirin in a Canadian cohort of treatment-naïve chronic hepatitis C patients with genotypes 2 or 3: results of the PoWer and RediPEN studies. Eur J Clin Microbiol Infect Dis 2016;35:597-609. [PMID: 26851949 DOI: 10.1007/s10096-016-2576-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
56 Thein HH, Qiao Y, Young SK, Zarin W, Yoshida EM, de Oliveira C, Earle CC. Trends in health care utilization and costs attributable to hepatocellular carcinoma, 2002-2009: a population-based cohort study. Curr Oncol 2016;23:e196-220. [PMID: 27330357 DOI: 10.3747/co.23.2956] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
57 Hull M, Klein M, Shafran S, Tseng A, Giguère P, Côté P, Poliquin M, Cooper C. CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core: Canadian guidelines for management and treatment of HIV/hepatitis C coinfection in adults. Can J Infect Dis Med Microbiol 2013;24:217-38. [PMID: 24489565 DOI: 10.1155/2013/781410] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]